{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-024955","form_type":"8-K","ticker":"VXRT","cik":"0000072444","company_name":"Vaxart, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.236848+00:00","generated_at":"2026-05-17T20:11:00.425932+00:00","sec_items":["1.01","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vaxart receives stop work order from BARDA on Phase 2b oral COVID-19 vaccine trial","bullets":["ATI/BARDA directed Vaxart to stop all work on Project Agreement RRPV-24-04-NGVx-003 for oral COVID-19 vaccine.","Company may only continue follow-up for already dosed participants in the 10,000-person cohort; enrollment about half complete.","No reason provided; DSMB had determined on July 14 that the study could proceed without modification.","Company expects a follow-up notice with further details; no additional funding or termination decision announced."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-024955","json":"https://secwatch.observer/filing/0001437749-25-024955.json","markdown":"https://secwatch.observer/filing/0001437749-25-024955.md","text":"https://secwatch.observer/filing/0001437749-25-024955.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/72444/000143774925024955/0001437749-25-024955-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/72444/000143774925024955/vxrt20250805_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:11:00.425932+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}